Morgan Stanley Sees Possible Good Things Ahead For Medtronic
In a report published Friday, Morgan Stanley analyst David R. Lewis reiterated an Equal-Weight rating on Medtronic (NYSE: MDT).
In the report, Morgan Stanley noted, “Reveal Linq may the sleeper product of HRS 2014. First generation Reveal was a tertiary product worth only ~$50-60 million in sales, but the second gen device is different. Reveal Linq makes major strides in innovation and telemetry and comes at a 20% price premium. With unusually strong clinical feedback, this device could open up a renewed global market for cardiac monitoring worth $500 million or more.”
Medtronic closed on Thursday at $59.43.
Latest Ratings for MDT
|Jan 2017||JP Morgan||Downgrades||Overweight||Neutral|
|Jan 2017||Morgan Stanley||Downgrades||Overweight||Equal-Weight|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.